US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Suspension of Trading

SUSPENSION OF TRADING Vancouver, British Columbia, 10 October 2024— Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that its shares have been suspended from trading on the Aquis Growth Market for failure to pay exchange fees pursuant to Rule 3.10 of the Aquis Stock Exchange Rulebook (Access) with effect from today, 10/10/2024.   The Directors of Mydecine take responsibility for this announcement. This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as

Annual and Q1 Financial Statements

MYDECINE ANNOUCES FILING OF AUDITED AND Q1 FINANCIAL STATEMENTS Vancouver, British Columbia, July 8, 2024— Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) is pleased to confirm that further to its news release dated June 14, 2024, the Company has filed on SEDAR+ its audited financial statements, accompanying management discussion and analysis and related CEO and CFO certifications for the period ended December 31, 2023 (the "Annual Filings") and its interim Q1 financial statements, accompanying management discussion and

Doc re: Bl-Weekly Status Report

MYDECINE PROVIDES Bl-WEEKLY STATUS REPORT Vancouver, British Columbia, June 14, 2024— Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order granted on May 2, 2024 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On May 3, 2024, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management’s

Bl-Weekly Status Report

MYDECINE PROVIDES Bl-WEEKLY STATUS REPORT Vancouver, British Columbia, June 3, 2024— Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order granted on May 2, 2024 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On May 3, 2024, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management’s

Mydecine Provides Bl-Weekly Status Report

MYDECINE PROVIDES Bl-WEEKLY STATUS REPORT Vancouver, British Columbia, May 17, 2024— Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order granted on May 2, 2024 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203").   On May 3, 2024, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management’

Mydecine applies for management cease trade order

MYDECINE APPLIES FOR MANAGEMENT CEASE TRADE ORDER VANCOUVER, British Columbia, 3 May 2024 — Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has requested a temporary Management Cease Trade Order (“MCTO”) from the British Columbia Securities Commission (“BCSC”) in connection with the Company’s filing of its audited annual financial statements (the “Audited Financial Statements”) and MD&A for the financial year ended December 31, 2023. The Company is requesting the MCTO in order to secure additional time to finalize its

Management cease trade order

MYDECINE RECEIVES MANAGEMENT CEASE TRADE ORDER VANCOUVER, British Columbia, 3 May 2024— Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has received a temporary Management Cease Trade Order (“MCTO”) on April 26, 2024, under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”) from the British Columbia Securities Commission (“BCSC”) in connection with the Company’s filing of its audited annual financial statements and MD&A for the financial year ended December 31, 2023. Pursuant to the MCTO, the chief

Restructuring transactions and annual general and special meeting

MYDECINE INNOVATIONS GROUP INC. ANNOUNCES RESTRUCTURING TRANSACTIONS AND ANNUAL GENERAL AND SPECIAL MEETING VANCOUVER, BC – (3 May 2024) Mydecine Innovations Group Inc. (CSE: MYCO) (FSE: 0NFA), (OTC: MYCOF) (AQSE: MYIG) (the “Company” or “Mydecine”) announced that it has entered into certain restructuring transactions in order to improve the financial health of the Company. Josh Bartch, CEO of the Company stated: "We are fully committed to the success of Mydecine and these restructuring efforts are intended to highlight that. Through these various restructuring efforts, the

Total Voting Rights

MYDECINE INNOVATIONS GROUP INC. (the "Company" or "Mydecine")   TOTAL VOTING RIGHTS     VANCOUVER, BC – (30 April 2024) In accordance with the FCA's Disclosure Guidance and Transparency Rules, as at 30 April 2024, the Company’s issued share capital consists of 61,755,385 Ordinary Shares of no par value, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 61,755,385. The above figure of 61,755,385 should be used by shareholders in the Company as the denominator for the

Closing of Share for Debt Settlement

MYDECINE INNOVATIONS GROUP INC. ANNOUNCES CLOSING OF SHARE FOR DEBT SETTLEMENT   VANCOUVER, BC – (16 April 2024) Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (FSE: 0NFA) (OTC: MYCOF) (the “Company” or “Mydecine”) announces that, further to the announcement on 9 April 2024, it has closed the debt settlement agreements (the “Settlement Agreements”) to fully settle outstanding debts owed to two creditors (the “Creditors”) for corporate back-office services rendered and an unpaid loan. Pursuant to the Settlement Agreements, the Company issued an aggregate of 3,628,208

SHARE FOR DEBT SETTLEMENT

MYDECINE INNOVATIONS GROUP INC. ANNOUNCES SHARE FOR DEBT SETTLEMENT   VANCOUVER, BC – (9 April 2024) Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (FSE: 0NFA) (OTC: MYCOF) (the “Company” or “Mydecine”) announces that it has entered into debt settlement agreements (the “Settlement Agreements”) to fully settle outstanding debts owed to two creditors (the “Creditors”) for corporate back office services rendered and an unpaid loan. Pursuant to the Settlement Agreements, the Company has agreed to issue an aggregate of 3,628,208 common shares (“Shares”) at a deemed price of $0.

Share for Debt Settlement

MYDECINE INNOVATIONS GROUP INC. ANNOUNCES SHARE FOR DEBT SETTLEMENT   VANCOUVER, BC – (21 March 2024) Mydecine Innovations Group Inc. (CSE: MYCO) (FSE: 0NFA), (OTC: MYCOF) (AQSE: MYIG) (the “Company” or “Mydecine”) announced that it has entered into a debt settlement agreement (the “Settlement Agreement”) to partially settle outstanding debts owed to a creditor (the “Creditor”) for legal services rendered. Pursuant to the Settlement Agreement, the Company has agreed to issue an aggregate of 2,941,176 common shares (“Shares”) at a deemed price of $0.017 per Share, based on a 20-day

Closing of Share for Debt Settlement

MYDECINE INNOVATIONS GROUP INC. ANNOUNCES CLOSING OF SHARE FOR DEBT SETTLEMENT   VANCOUVER, BC – (23 February 2024) Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE:MYIG) (FSE: 0NFA), (OTC: MYCOF) (the “Company” or “Mydecine”) announces that it has closed a debt settlement (the “Debt Settlement”) to partially settle outstanding debts owed to a creditor (the “Creditor”) for legal services rendered. Pursuant to the Debt Settlement, the Company issued an aggregate of 2,618,543 common shares (“Shares”) at a deemed price of $0.02 per Share, based on a 20-day VWAP (the “Share

Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

  Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds   VANCOUVER, British Columbia, 08 February 2024 (GLOBE NEWSWIRE) – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company’s MYCO-005 and MYCO-006 families.

Mydecine Innovations Group Announces Director Resignation

  Mydecine Innovations Group Announces Director Resignation     VANCOUVER, British Columbia, 02 February 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, announces that Neil Stevenson-Moore has resigned as a director of the Company. The Company would like to thank Mr. Stevenson-Moore for his contributions to the Company and wishes him well in this future endeavors.   The

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

  Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound     VANCOUVER, British Columbia, 18 December 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for their MYCO-005 compound, "Novel Aza-Substituted Psilocin

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENTS

  MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENTS     VANCOUVER, BC, 31 October 2023 – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with: (i) its previously announced Common Share Subscription Agreement (the “Opensky

Q4 2023 Business Update

[A blue and white logo Description automatically generated]           Mydecine Provides Q4 2023 Business Update   VANCOUVER, British Columbia, 26 Oct. 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD with psychedelic therapeutics, is pleased to address its shareholders and provide a general update on

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

[A blue and white logo Description automatically generated]             Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK     VANCOUVER, BC, 13 October 2023 – Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces that it has completed its admission to the Access

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media